2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Amylases
  5. Amylases Inhibitor

Amylases Inhibitor

Amylases Inhibitors (38):

Cat. No. Product Name Effect Purity
  • HY-N0668
    Rubusoside
    		Inhibitor 98.58%
    Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
  • HY-162673
    α-Amylase/α-Glucosidase-IN-16
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of α-amylase and α-Glucosidase with IC50 values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM).
  • HY-161764
    α-Glucosidase-IN-67
    		Inhibitor
    α-Glucosidase-IN-67 (compound 5k) is a potent α-Glucosidase inhibitor with IC50 values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes.
  • HY-161944
    α-Amylase-IN-8
    		Inhibitor
    α-Amylase-IN-8 (compound 44) ​​is an α-amylase inhibitor (IC50=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes.
  • HY-149008
    α-Amylase-IN-3
    		Inhibitor 99.49%
    α-Amylase-IN-3 (Compound 4) is a none-competitive type of α-Amylase inhibitor with an IC50 value of 18.04 μM, which also has radical scavenging activities (DPPH and ABTS) with IC50 values of 16.04 μM (DPPH) and 16.99 μM (ABTS), respectively. α-Amylase-IN-3 has good protein–ligand interactions profile against α-Amylase. α-Amylase-IN-3 may have pharmacological activities such as anti-oxidative, anti-inflammatory inhibitory, which is helpful for the development of diabetes and oxidative stress associated disease.
  • HY-162373
    α-Amylase/α-Glucosidase-IN-10
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects.
  • HY-149557
    α-Amylase/α-Glucosidase-IN-5
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity.
  • HY-161355
    α-Amylase/α-Glucosidase-IN-9
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes.
  • HY-N12688
    2,3-Dihydrocalodenin B
    		Inhibitor
    2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against α-glucosidase and α-amylase, with IC50 values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes.
  • HY-156380
    α-Amylase/α-Glucosidase-IN-6
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities.
  • HY-W727627
    5-O-Coumaroylquinic acid
    		Inhibitor
    5-O-Coumaroylquinic acid is a potent, reversible, non-competitive α-amylase inhibitor with an IC50 value of 69.39 μM. 5-O-Coumaroylquinic acid can be used in diabetes research.
  • HY-155961
    Antidiabetic agent 2
    		Inhibitor
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels.
  • HY-N9916
    8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside
    		Inhibitor
    8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside (Compound 3) is natural product that can be isolated from Bidens bipinnata. 8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside shows 22% inhibition against α-amylase at 0.556 mg/mL.
  • HY-163439
    α-Amylase/α-Glucosidase-IN-12
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC50 of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research.
  • HY-157537
    α-Amylase-IN-5
    		Inhibitor
    α-Amylase-IN-5 (compound 3a) is a α-amylase inhibitor, with an IC50 of 18.8 mM.
  • HY-149313
    α‑Amylase-IN-1
    		Inhibitor
    α Amylase-IN-1 (Compound 11) is an α-Amylase inhibitor with an IC50 value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging DPPH free radicals. IC50 can be used in the study of diabetes and oxidative stress-related diseases.
  • HY-N12263
    3,5,6,7,8,4'-Hexamethoxyflavone
    		Inhibitor
    3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of α-Amylase with the inhibitory activity of 28.3% at 500 μM.
  • HY-N0668R
    Rubusoside (Standard)
    		Inhibitor
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
  • HY-161461
    E234G HYPE-IN-1
    		Inhibitor
    E234G HYPE-IN-1 (Compound I2.10) is an inhibitor of AMPylation directed by the Huntingtin-interacting protein E (HYPE), possessing low micromolar bioactivity, low cytotoxicity, and blood-brain barrier permeability. E234G HYPE-IN-1 can inhibit the AMPylation of B-cell immunoglobulin-binding protein (BiP), the primary substrate of HYPE. E234G HYPE-IN-1 is suitable for development as a HYPE-specific therapeutic agent for clinical conditions such as neurodegenerative diseases and diabetes.
  • HY-159491
    DPP-4-IN-11
    		Inhibitor
    DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM).